{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:52:18Z","timestamp":1774936338885,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011826"],"award-info":[{"award-number":["2023J011826"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to develop and validate a nomogram model integrating routinely available parameters, making it applicable to primary healthcare settings for optimizing prostate cancer (PCa) risk stratification in patients with elevated prostate-specific antigen (PSA) levels, aiming to reduce unnecessary biopsies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included a retrospective cohort of 2, 844 patients who underwent prostate biopsy (885 malignant and 1, 959 benign cases), who were randomly allocated to a training set and an internal validation set in a 7:3 ratio. Independent predictive factors were selected through univariate analyses and multivariate logistic regression analyses, and a nomogram was constructed. The model\u2019s performance was evaluated using Receiver Operating Characteristic (ROC) curve analysis, precision-recall (PR) curves, calibration curve, and decision curve analysis (DCA). Further validation was conducted using an external independent dataset (\n                      <jats:italic>n<\/jats:italic>\n                      = 281; 93 malignant and 188 benign cases) to assess the model\u2019s generalizability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The nomogram model incorporated prostate volume, total PSA (tPSA), free-to-total PSA ratio (f\/t PSA), and age, demonstrating discriminative performance with AUC values of 0.816 (95% CI: 0.796\u20130.836; training set), 0.833 (95% CI: 0.802\u20130.862; internal validation set), and 0.776 (95% CI: 0.720\u20130.832; external validation set). Its clinically acceptable performance outperformed that of individual parameters in the training set (all p-values &amp;lt;0.001 by Delong\u2019s test). The ROC curve and PR curve both demonstrated the robust predictive performance of the prediction model across all three study cohorts. The calibration curve showed strong agreement between the predicted probability and actual risk. DCA confirmed clinical net benefit across a wide range of risk thresholds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This nomogram provides a non-invasive, cost-effective, individualized PCa risk assessment tool for Chinese patients with elevated PSA levels. Its generalizability was confirmed through external validation, demonstrating effectiveness in optimizing biopsy decisions and suitability for primary healthcare settings, thereby reducing healthcare burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1787090","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:15:27Z","timestamp":1774930527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary healthcare-friendly prostate cancer prediction model using routine clinical parameters: a multicenter study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ming","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Ultrasound, Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]},{"name":"Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhongshan Hospital, Fudan University (Xiamen Branch)","place":["Xiamen, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShuPing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxin","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]},{"name":"Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiguang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Statistics Room, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorong","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, Second Affiliated Hospital of Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: A review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"106588","DOI":"10.1016\/j.jsbmb.2024.106588","article-title":"PSA, an outdated biomarker for prostate cancer: In search of a more specific biomarker, citrate takes the spotlight","volume":"243","author":"Galey","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-024-03804-4","article-title":"Prostate Specific Antigen (PSA) testing in a general practice 2009-2019","volume":"194","author":"Maguire","year":"2025","journal-title":"Ir J Med Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11934-018-0828-6","article-title":"Improving the specificity of PSA screening with serum and urine markers","volume":"19","author":"Kearns","year":"2018","journal-title":"Curr Urol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"116773","DOI":"10.1016\/j.bios.2024.116773","article-title":"Explainable artificial intelligence-driven prostate cancer screening using exosomal multi-marker based dual-gate FET biosensor","volume":"267","author":"Choi","year":"2025","journal-title":"Biosens Bioelectron"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.0c06946","article-title":"Noninvasive precision screening of prostate cancer by urinary multimarker sensor and artificial intelligence analysis","volume":"15","author":"Kim","year":"2021","journal-title":"ACS Nano"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2011.04.001","article-title":"Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer","volume":"31","author":"Salami","year":"2013","journal-title":"Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-1527","article-title":"A genetic risk score to personalize prostate cancer screening, applied to population data","volume":"29","author":"Huynh-Le","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/genes10090641","article-title":"Gene\u2013Prostate-specific-antigen-guided personalized screening for prostate cancer","volume":"10","author":"Yang","year":"2019","journal-title":"Genes (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu084","article-title":"Individualized prostate-specific antigen threshold values to avoid overdiagnosis of prostate cancer and reduce unnecessary biopsy in elderly men","volume":"44","author":"Kanao","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0082-5","article-title":"The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort","volume":"22","author":"M\u00f6ller","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0136735","DOI":"10.1371\/journal.pone.0136735","article-title":"Incorporating known genetic variants does not improve the accuracy of PSA testing to identify high risk prostate cancer on biopsy","volume":"10","author":"Gilbert","year":"2015","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00205-2","article-title":"An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases","volume":"52","author":"Carlson","year":"1998","journal-title":"Urology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.11.012","article-title":"Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators","volume":"61","author":"Roobol","year":"2012","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.06.057","article-title":"Complications after prostate biopsy: data from SEER-medicare","volume":"186","author":"Loeb","year":"2011","journal-title":"J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2012.111","article-title":"A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer","volume":"15","author":"Tang","year":"2013","journal-title":"Asian J Androl"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1038\/s41598-020-58836-4","article-title":"A predictive model for prostate cancer incorporating PSA molecular forms and age","volume":"10","author":"Oto","year":"2020","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06436-w","article-title":"Automated multiparametric localization of prostate cancer based on B-mode, shear-wave elastography, and contrast-enhanced ultrasound radiomics","volume":"30","author":"Wildeboer","year":"2020","journal-title":"Eur Radiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-025-04903-1","article-title":"Novel ultrasound scoring system to guide cognitive fusion-targeted biopsy: a prospective study","author":"Qin","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41391-023-00708-9","article-title":"Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET\/CT","volume":"27","author":"Ditonno","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17562872221145625","DOI":"10.1177\/17562872221145625","article-title":"Multiparametric ultrasound of prostate: role in prostate cancer diagnosis","volume":"14","author":"Kaneko","year":"2022","journal-title":"Ther Adv Urol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-011-0818-5","article-title":"Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group","volume":"30","author":"Ankerst","year":"2012","journal-title":"World J Urol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.eururo.2018.05.003","article-title":"A contemporary prostate biopsy risk calculator based on multiple heterogeneous cohorts","volume":"74","author":"Ankerst","year":"2018","journal-title":"Eur Urol"},{"key":"B26","article-title":"Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population","volume":"24","author":"Zhu","year":"2018","journal-title":"Zhonghua Nan Ke Xue"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.3390\/cancers15164105","article-title":"Comparative assessment of different ultrasound technologies in the detection of prostate cancer: A systematic review and meta-analysis","volume":"15","author":"Alghamdi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-019-02305-8","article-title":"Prostate cancer and the role of biomarkers","volume":"45","author":"Nevo","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the european randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12957-019-1573-0","article-title":"Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis","volume":"17","author":"Xiang","year":"2019","journal-title":"World J Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e230118","DOI":"10.1148\/ryai.230118","article-title":"Identification of precise 3D CT radiomics for habitat computation by machine learning in cancer","volume":"6","author":"Prior","year":"2024","journal-title":"Radiol Artif Intell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04086-0","article-title":"A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis","volume":"41","author":"Wang","year":"2023","journal-title":"World J Urol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12916-023-02964-x","article-title":"Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study","volume":"21","author":"Zhang","year":"2023","journal-title":"BMC Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2023.2277366","article-title":"Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification","volume":"23","author":"Ferro","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and validation of an 18-gene urine test for high-grade prostate cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.05.014","article-title":"Prediction of clinically significant prostate cancer by a specific collagen-related transcriptome, proteome, and urinome signature","volume":"8","author":"Heidegger","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"18910","DOI":"10.1038\/s41598-024-69804-7","article-title":"Evaluation of prostate cancer detection using micro-ultrasound versus MRI through co-registration to whole-mount pathology","volume":"14","author":"Pensa","year":"2024","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3791\/67873","article-title":"A cognitive fusion-guided prostate biopsy using multiparametric magnetic resonance imaging and transrectal ultrasound","volume":"217","author":"Dai","year":"2025","journal-title":"J Vis Exp"},{"key":"B41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00345-025-05609-1","article-title":"Learning curve on prostate fusion biopsies: key insights","volume":"43","author":"Lepr\u00eatre","year":"2025","journal-title":"World J Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:15:31Z","timestamp":1774930531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1787090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1787090"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1787090","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1787090"}}